Plomer, Eva; Früh, Martin; Lauber, Arno; Demmer, Izadora; Jochum, Wolfram; Koster, Kira-Lee (2024). Prolonged Response to Afatinib and Crizotinib in a Rare Case of EGFR-, HER2-, MET- and ROS1-Alterated Lung Adenocarcinoma. International journal of molecular sciences, 25(11) MDPI 10.3390/ijms25115698
|
Text
ijms-25-05698-v3.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (1MB) | Preview |
We present the case of a 70-year-old never-smoking female patient with epidermal growth factor receptor (EGFR) p.L858R-mutated metastatic non-small cell lung cancer (NSCLC). After three months of first-line treatment with erlotinib, progression occurred and platinum/pemetrexed was initiated, followed by a response for more than two years. After the progression, the molecular testing of a vertebral metastasis revealed a ROS proto-oncogene 1 (ROS1) translocation and a human epidermal growth factor receptor 2 (HER2) p.S310F mutation, in addition to the known EGFR p.L858R mutation. Crizotinib then led to a durable response of 17 months. The molecular retesting of the tumour cells obtained from the recurrent pleural effusion revealed the absence of the ROS1 translocation, whereas the EGFR and HER2 mutations were still present. Afatinib was added to the crizotinib, and the combination treatment resulted in another durable response of more than two years. The patient died more than 7 years after the initial diagnosis of metastatic NSCLC. This case demonstrates that the repeated molecular testing of metastatic NSCLC may identify new druggable genomic alterations that can impact the patient management and improve the patient outcome.
Item Type: |
Journal Article (Further Contribution) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
UniBE Contributor: |
Früh, Martin |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1422-0067 |
Publisher: |
MDPI |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
20 Jun 2024 11:07 |
Last Modified: |
22 Jun 2024 03:01 |
Publisher DOI: |
10.3390/ijms25115698 |
PubMed ID: |
38891886 |
Uncontrolled Keywords: |
EGFR-mutated NSCLC NSCLC drug combinations molecular pathology targeted therapies |
BORIS DOI: |
10.48350/197955 |
URI: |
https://boris.unibe.ch/id/eprint/197955 |
Actions (login required)
 |
Edit item |